“I am excited to partner with Exquiron as our technology is innovative to the discovery field and coupled with Exquiron’s additional assay capabilities and compound collection we can offer a comprehensive solution to our clients.
SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.
Stephan Fasler Ph.D., CEO of Exquiron commented “We have previously collaborated with SAMDI Tech; the company has been our first choice for entering into this partnership. We are impressed by the novelty and quality of SAMDI Tech’s label-free assay technology, which, coupled with their excellent assay development services, renders SAMDI Tech a company to absolutely work with.”
About SAMDI Tech, Inc:
SAMDI Tech, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI’s pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at www.samditech.com
About Exquiron Biotech AG:
Exquiron, headquartered in Reinach BL, Switzerland, is a company dedicated to contract research in early stage drug discovery. Its services span from assay development for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Exquiron’s team brings extensive skills and know-how in all areas of the hit identification process, including broad target class coverage, applicable technologies, data processing and evaluation.